Marketing-authorisation holder · United States
Teva Pharmaceuticals, Inc.
163 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
163 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 163
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ACETAMINOPHEN AND CODEINE PHOSPHATE300mg; 15mg | 300mg; 30mg | 300mg; 60mg · Capsule | Paracetamol, Codeine | United States | Not marketed | 1983 |
| ADIPEX-P37.5mg · Capsule | Phentermine | United States | Not marketed | 1983 |
| ADIPEX-P37.5mg · Tablet | Phentermine | United States | Marketed | 1980 |
| AIRDUO DIGIHALER0.055mg/inh; 0.014mg base/inh | 0.113mg/inh; 0.014mg base/inh | 0.232mg/inh; 0.014mg base/inh · Powder | Fluticasone, Salmeterol | United States | Not marketed | 2017 |
| AIRDUO RESPICLICK0.055mg/inh; 0.014mg base/inh | 0.113mg/inh; 0.014mg base/inh | 0.232mg/inh; 0.014mg base/inh · Powder | Fluticasone, Salmeterol | United States | Marketed | 2017 |
| AJOVY150mg/ml · Injectable | Fremanezumab | United States | Marketed | 2018 |
| ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE0.083% base; 0.017% · Solution | Salbutamol, Ipratropium bromide | United States | Marketed | 2006 |
| ALVAIZ18mg base | 36mg base | 54mg base | 9mg base · Tablet | Eltrombopag choline | United States | Marketed | 2023 |
| ALYQ20mg · Tablet | Tadalafil | United States | Marketed | 2019 |
| AMOXICILLIN125mg | 200mg | 250mg | 400mg · Tablet, chewable | Amoxicillin | United States | Marketed | 1992 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM200mg; 28.5mg base | 400mg; 57mg base · Tablet, chewable | Amoxicillin, Clavulanic acid | United States | Marketed | 2002 |
| AMOXICILLIN PEDIATRIC50mg/ml · For suspension | Amoxicillin | United States | Marketed | 1982 |
| ARGATROBAN IN 0.9% SODIUM CHLORIDE250mg/250ml (1mg/ml) · Injectable | Argatroban | United States | Not marketed | 2014 |
| ARIPIPRAZOLE10mg | 15mg | 20mg | 2mg | 30mg | 5mg · Tablet | Aripiprazole | United States | Marketed | 2012 |
| ARMONAIR DIGIHALER0.03mg/inh | 0.055mg/inh | 0.113mg/inh | 0.232mg/inh · Powder | Fluticasone | United States | Not marketed | 2017 |
| ARMONAIR RESPICLICK0.03mg/inh | 0.055mg/inh | 0.113mg/inh | 0.232mg/inh · Powder | Fluticasone | United States | Not marketed | 2017 |
| AUSTEDO XR12mg | 18mg | 24mg | 30mg | 36mg | 42mg | 48mg | 6mg · Tablet, extended release | Deutetrabenazine | United States | Marketed | 2023 |
| AZILECT0.5mg base | 1mg base · Tablet | Rasagiline | United States | Marketed | 2006 |
| BICALUTAMIDE50mg · Tablet | Bicalutamide | United States | Marketed | 2009 |
| BUDESONIDE0.25mg/2ml | 0.5mg/2ml | 1mg/2ml · Suspension | Budesonide | United States | Marketed | 2008 |
| BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE0.08mg/inh; 0.0045mg/inh | 0.16mg/inh; 0.0045mg/inh · Aerosol, metered | Budesonide, Formoterol | United States | Marketed | 2026 |
| CABOZANTINIB20mg | 40mg | 60mg · Tablet | Cabozantinib | United States | Marketed | 2022 |
| CARBAMAZEPINE100mg | 200mg | 300mg · Capsule, extended release | Carbamazepine | United States | Marketed | 2011 |
| CASSIPA16mg base; 4mg base · Film | Buprenorphine, Naloxone | United States | Not marketed | 2018 |
| CEFACLOR250mg base | 500mg base · Capsule | Cefaclor | United States | Marketed | 1979 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 163 | 147 | 16 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.